Abviris Overview
- Founded
-
2014

- Status
-
Private
- Employees
-
8

- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$2.41M
- Investors
-
3
Abviris General Information
Description
Developer of an immune-oncology diagnostic test designed for early detection of HPV-induced cancer. The company's product addresses the problem of cancer caused by the human papillomavirus (HPV) and fights HPV-induced tumors, including head and neck cancer, penile and anal tumors and also vaginal, vulvar and cervical cancer, enabling physicians to detect cancer and get results of the examination available within minutes.
Contact Information
Website
www.abviris.com
Formerly Known As
Abviris Deutschland
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Primary Office
- Beimoorkamp 6
- 22926 Ahrensburg
- Germany
+49 04102 0000000
Abviris Timeline
Abviris Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC | 16-Mar-2021 | $2.41M | 00.000 | 000.00 | Completed | Generating Revenue |
3. Later Stage VC (Series A) | 26-Jun-2019 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
2. Accelerator/Incubator | 01-Apr-2019 | $1.09M | Completed | Generating Revenue | ||
1. Seed Round | 21-Jan-2016 | $1.09M | $1.09M | 00.000 | Completed | Generating Revenue |
Abviris Patents
Abviris Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2020501162-A | Serum test for therapeutic control of hpv16 positive cancer | Pending | 13-Dec-2016 | 0000000000 | |
EP-3384292-A1 | Serologic test for therapy control of hpv16 positive carcinoma | Granted | 13-Dec-2016 | 0000000000 | |
US-20200408768-A1 | Serologic test for therapy control of hpv16 positive carcinoma | Pending | 13-Dec-2016 | 000000000000 | |
ES-2880489-T3 | Serological test for the control of positive hpv16 carcinoma therapy | Active | 13-Dec-2016 | 000000000000 | |
US-10852303-B2 | Serologic test for therapy control of hpv16 positive carcinoma | Active | 13-Dec-2016 | G01N33/57407 | 0 |
Abviris Executive Team (4)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Sven Klose | Managing Director & Chief Financial Officer | ||
Ralf Hilfrich | Co-Founder & Advisor |
Abviris Board Members (2)
Name | Representing | Role | Since |
---|---|---|---|
Fabian Mohr Ph.D | Self | Board Member | 000 0000 |
Philipp Rittershaus Ph.D | High-Tech Gründerfonds | Board Member | 000 0000 |
Abviris Signals
Abviris Investors (3)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
German Accelerator | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
High-Tech Gründerfonds | Venture Capital | Minority | 000 0000 | 000000 0 | |
Mittelständische Beteiligungsgesellschaft Schleswig-Holstein | Venture Capital | Minority | 000 0000 | 000000 0 |